Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | IL18 | Q14116 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8852392 | 0.88 | PARP15 (0.63) | MAOBPARP15PARP10PARP2MAPT | |
| SCHEMBL7041250 | 0.88 | PARP15 (0.63) | MAOBPARP15PARP10PARP2MAPT | |
| SCHEMBL154636 | 0.85 | — | — | |
| Water SCHEMBL27994834 | 0.85 | MAOB (0.73) | MAOBMAOACYP19A1CA2CA9 | |
| SCHEMBL14656590 | 0.83 | MAOB (0.70) | MAOBMAOACYP19A1CA2CA9 | |
| SCHEMBL6827721 | 0.83 | MAOB (0.70) | MAOBMAOACYP19A1CA2CA9 | |
| Hydrochloric Acid SCHEMBL30722972 | 0.83 | MAOB (0.70) | MAOBMAOACYP19A1CA2CA9 | |
| SCHEMBL29582194 | 0.81 | PARP15 (0.57) | MAOBPARP15PARP10PARP2MAPT | |
| SCHEMBL2532878 | 0.81 | CYP19A1 (0.51) | MAOBMAOAPARP15PARP10PARP2 | |
| SCHEMBL5787364 | 0.81 | PDE4A (0.49) | MAOBMAOAMAPTCYP19A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2025-02-20 | — | — | US | disclosed |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118359503-A | Synthesis method of copper-catalyzed diaryl ether promoted by visible light | 新疆大学 | 2024-07-19 | — | — | CN | disclosed |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | MAOB 1003/4885MAOA 3607/4885PARP15 2209/4885 |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | MAOB 819/4885MAOA 1681/4885PARP15 510/4885 |
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | MAOB 819/4885MAOA 1681/4885PARP15 510/4885 |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | MAOB 1003/4885MAOA 3607/4885PARP15 2209/4885 |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | MAOB 819/4885MAOA 1681/4885PARP15 510/4885 |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | MAOB 819/4885MAOA 1681/4885PARP15 510/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | MAOB 2144/4885MAOA 3368/4885PARP15 331/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | MAOB 819/4885MAOA 1681/4885PARP15 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.